Opthea Stock Today

OPT Stock  USD 4.21  0.10  2.43%   

Performance

19 of 100

 
Weak
 
Strong
Solid

Odds Of Distress

Over 57

 
High
 
Low
Above Average
Opthea is selling for under 4.21 as of the 11th of November 2024; that is 2.43 percent increase since the beginning of the trading day. The stock's last reported lowest price was 4.12. Opthea has over 57 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat solid returns during the last 90 days. Equity ratings for Opthea are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of October 2024 and ending today, the 11th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of April 2012
Category
Healthcare
Classification
Health Care
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Opthea operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 153.89 M outstanding shares of which 71.72 K shares are now shorted by investors with about 1.82 days to cover. More on Opthea

Moving together with Opthea Stock

  0.81DMAC DiaMedica TherapeuticsPairCorr

Moving against Opthea Stock

  0.86VALN Valneva SE ADRPairCorr
  0.86VCNX VaccinexPairCorr
  0.75DRMA Dermata TherapeuticsPairCorr
  0.6VCEL Vericel Corp OrdPairCorr
  0.55ME 23Andme HoldingPairCorr
  0.31DRRX DurectPairCorr

Opthea Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Old NameOptizen Labs SA
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Australia All Ordinaries, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover6.0E-47.0E-4
Notably Down
Slightly volatile
Total Current Liabilities67.3 M64.1 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total210.6 M200.5 M
Sufficiently Up
Slightly volatile
Total Assets198.2 M188.8 M
Sufficiently Up
Slightly volatile
Total Current Assets197.6 M188.2 M
Sufficiently Up
Slightly volatile
Debt Levels
Opthea can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Opthea's financial leverage. It provides some insight into what part of Opthea's total assets is financed by creditors.
Liquidity
Opthea has 200.63 M in debt. Opthea has a current ratio of 4.87, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Opthea to invest in growth at high rates of return.

Begin Period Cash Flow

93.65 Million
Opthea (OPT) is traded on NASDAQ Exchange in USA. It is located in 650 Chapel Street, South Yarra, VIC, Australia, 3141 and employs 33 people. Opthea is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 669.85 M. Opthea runs under Biotechnology sector within Health Care industry. The entity has 153.89 M outstanding shares of which 71.72 K shares are now shorted by investors with about 1.82 days to cover. Opthea has about 44.63 M in cash with (161.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01.
Check Opthea Probability Of Bankruptcy
Ownership Allocation
Opthea owns a total of 153.89 Million outstanding shares. Roughly 96.03 pct. of Opthea outstanding shares are held by general public with 3.97 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Opthea Ownership Details

Opthea Stock Institutional Holders

InstituionRecorded OnShares
Vgi Partners Pty Ltd2024-06-30
2.9 M
Jane Street Group Llc2024-06-30
0.0
Baker Bros Advisors Lp2024-06-30
2.2 M
Victory Capital Management Inc.2024-06-30
840 K
Teacher Retirement System Of Texas2024-06-30
269.4 K
Millennium Management Llc2024-06-30
71.2 K
Bank Of Montreal2024-06-30
48.6 K
Bmo Capital Markets Corp.2024-06-30
48.6 K
Stratos Wealth Partners, Ltd2024-09-30
29.6 K
Royal Bank Of Canada2024-06-30
K
Frazier Financial Advisors, Llc2024-06-30
750
View Opthea Diagnostics

Opthea Historical Income Statement

At this time, Opthea's Interest Expense is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 202.4 M in 2024, despite the fact that EBIT is likely to grow to (183 M). View More Fundamentals

Opthea Stock Against Markets

Opthea Corporate Management

Jen WattsVP OperationsProfile
Karen CPAVP SecretaryProfile
CPA CPAChief OfficerProfile
MD MAChief AdvisorProfile
Sarika GulharExecutive ResourcesProfile
Michael GeromettaManufacturing ChemistryProfile
Peter MBAChief OfficerProfile

Additional Tools for Opthea Stock Analysis

When running Opthea's price analysis, check to measure Opthea's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opthea is operating at the current time. Most of Opthea's value examination focuses on studying past and present price action to predict the probability of Opthea's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opthea's price. Additionally, you may evaluate how the addition of Opthea to your portfolios can decrease your overall portfolio volatility.